(NASDAQ: LIVN) Livanova's forecast annual revenue growth rate of 8.18% is not forecast to beat the US Medical Devices industry's average forecast revenue growth rate of 9.64%, and while it is not forecast to beat the US market's average forecast revenue growth rate of 23.15%.
Livanova's revenue in 2026 is $1,348,962,000.On average, 14 Wall Street analysts forecast LIVN's revenue for 2026 to be $81,962,896,027, with the lowest LIVN revenue forecast at $77,266,820,705, and the highest LIVN revenue forecast at $85,949,099,498. On average, 14 Wall Street analysts forecast LIVN's revenue for 2027 to be $87,150,421,092, with the lowest LIVN revenue forecast at $81,143,813,122, and the highest LIVN revenue forecast at $92,010,312,995.
In 2028, LIVN is forecast to generate $93,757,689,859 in revenue, with the lowest revenue forecast at $84,693,172,377 and the highest revenue forecast at $102,767,601,814.